|
Market Closed -
Other stock markets
|
After hours 05:00:00 | |||
| 52.15 USD | +0.38% |
|
52.16 | +0.02% |
| 12-05 | The Most Overhyped PCE Print in Wall Street History |  |
| 12-05 | Bristol Myers Gets FDA Expanded Approval of Breyanzi | DJ |
| Capitalization | 106B 91.26B 85.49B 79.68B 147B 9,555B 160B 1T 386B 4,513B 398B 390B 16,500B | P/E ratio 2025 * |
12.3x | P/E ratio 2026 * | 11.2x |
|---|---|---|---|---|---|
| Enterprise value | 139B 120B 112B 105B 193B 12,546B 210B 1,313B 507B 5,925B 523B 512B 21,666B | EV / Sales 2025 * |
2.91x | EV / Sales 2026 * | 3.02x |
| Free-Float |
67.93% | Yield 2025 * |
4.74% | Yield 2026 * | 4.88% |
Last Transcript: Bristol-Myers Squibb Company
| 1 day | +0.02% | ||
| 1 week | +6.00% | ||
| Current month | +6.00% | ||
| 1 month | +12.22% | ||
| 3 months | +10.63% | ||
| 6 months | +9.01% | ||
| Current year | -7.80% |
| 1 week | 48.22 |  | 52.51 |
| 1 month | 45.26 | | 52.51 |
| Current year | 42.52 | | 63.33 |
| 1 year | 42.52 | | 63.33 |
| 3 years | 39.35 | | 80.67 |
| 5 years | 39.35 | | 81.44 |
| 10 years | 39.35 | | 81.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 01/11/2023 | |
David Elkins
DFI | Director of Finance/CFO | 57 | 20/11/2019 |
| Compliance Officer | - | 01/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 01/04/2024 | |
Peter Arduini
BRD | Director/Board Member | 60 | 01/04/2016 |
Theodore Samuels
BRD | Director/Board Member | 70 | 21/02/2017 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 12.97% | 303 M€ | -21.21% | - |
| 4.01% | 26 M€ | +11.73% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.38% | +6.00% | -11.37% | -35.38% | 106B | |
| -0.41% | -6.06% | +22.37% | +173.58% | 905B | |
| -0.27% | -2.41% | +35.05% | +12.95% | 487B | |
| -1.15% | -0.71% | +28.33% | +37.90% | 400B | |
| +0.26% | +1.14% | +21.30% | +0.44% | 330B | |
| +0.58% | -2.73% | +28.01% | +20.71% | 281B | |
| +0.19% | +2.49% | +18.48% | +24.80% | 255B | |
| -1.16% | -4.87% | -3.70% | -9.35% | 248B | |
| +1.24% | -2.33% | -59.84% | -31.25% | 214B | |
| -3.02% | -4.51% | +20.25% | +15.79% | 178B | |
| Average | -0.18% | -1.40% | +9.89% | +21.02% | 340.27B | |
| Weighted average by Cap. | -0.09% | -2.52% | +16.72% | +53.13% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 47.96B 41.23B 38.62B 36B 66.49B 4,316B 72.32B 452B 174B 2,039B 180B 176B 7,454B | 44.05B 37.86B 35.47B 33.06B 61.07B 3,964B 66.42B 415B 160B 1,872B 165B 162B 6,846B |
| Net income | 8.26B 7.1B 6.65B 6.2B 11.45B 744B 12.46B 77.83B 30.05B 351B 31.01B 30.35B 1,284B | 9.26B 7.96B 7.45B 6.95B 12.83B 833B 13.96B 87.2B 33.67B 394B 34.75B 34B 1,439B |
| Net Debt | 33.24B 28.57B 26.77B 24.95B 46.08B 2,992B 50.12B 313B 121B 1,413B 125B 122B 5,166B | 26.75B 22.99B 21.54B 20.08B 37.08B 2,407B 40.33B 252B 97.28B 1,137B 100B 98.25B 4,157B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 52.15 $ | +0.38% | 15,667,697 |
| 04/12/25 | 51.95 $ | +1.94% | 20,473,113 |
| 03/12/25 | 50.96 $ | +5.62% | 27,120,129 |
| 02/12/25 | 48.25 $ | -1.89% | 14,475,664 |
| 01/12/25 | 49.18 $ | -0.04% | 11,772,868 |
Delayed Quote Nyse, December 06, 2025 at 01:00 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BMY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition